Background: Cannabis, the most commonly used illicit drug in the US, is associated with adverse and beneficial effects. To better understand the full spectrum of health consequences, biomarkers that accurately classify cannabis use are needed. DNA methylation (DNAm) is an excellent candidate, yet no blood-based epigenome-wide association studies (EWAS) in humans exist.
INTRODUCTION
Cannabis use is highly prevalent with 45% of Americans aged 12 or older reporting lifetime use (defined here as ever-use of cannabis), and 15% reporting use in the past year (1). These numbers are expected to grow due to increasing legalization of both medical and recreational cannabis use. As of 2019, 33 US States have legalized cannabis for medical purposes, 10 of which have also legalized recreational use (2).
Cannabis use has been associated with various adverse effects, including impaired cognitive and motor function, altered judgement, paranoia, psychosis, cannabis use disorder, altered brain development, chronic bronchitis, and diminished life satisfaction and achievement (3) . In contrast, evidence exists supporting therapeutic benefits for various clinical conditions (e.g., glaucoma, acquired immune deficiency syndrome, nausea, chronic pain, inflammation) (3) . Efforts to better understand the full spectrum of cannabis-related health consequences have been hindered as a result of underreporting (e.g., due to social stigma associated with use) and the absence of available biomarkers that can accurately quantify cannabis usage patterns.
Currently available biomarkers of cannabis exposure, such as urinary metabolites, suffer limitations. These existing biomarkers have limited windows for detection, are largely restricted to acute exposures (e.g., ranging from 3 to >30 days, depending on the frequency of cannabis use (4)), and are unable to quantify cumulative exposure, which may prove to be a better indicator of subsequent health outcomes (4) .
Epigenetic modifications represent promising candidates for biomarker research.
DNA methylation (DNAm), the most commonly studied form of epigenetic modification, is defined by the presence of a methyl group (-CH3) most often at the carbon-5 position of a cytosine nucleotide in the context of CpG sites (adjacent cytosine and guanine nucleotides linked by a phosphate group). DNAm can be influenced by genetic factors, disease, environmental exposures, and lifestyle, and can vary across developmental stages of life (e.g., infancy, childhood, and adulthood), tissues, and cell types. An important feature of exposure-related DNAm changes is that they can either be persistent (i.e., stable changes) or reversible (i.e., return to prior state) once the exposure is no longer present. This combination of both persistent and reversible changes has value for biomarker development and has been observed, for example, in relation to tobacco smoking where only a subset of DNAm changes identified between current versus never smokers are also found between former versus never smokers (5, 6) .
Research geared towards understanding epigenetic changes related to cannabinoids, which encompass endocannabinoids (endogenous ligands), natural cannabinoids (derived from cannabis and includes Δ 9 -tetrahydrocannabinol [THC] and cannabidiol), and synthetic cannabinoids, is growing. However, studies to date are largely based on animal studies and human candidate gene studies (7, 8) , with only one epigenome-wide study in human sperm (9) . To begin to address this gap in the field, we report the first blood-based EWAS of lifetime cannabis (ever vs. never) use with discovery (N=1,730) and replication (N=853) samples. We extended our EWAS findings by using genetic information to help distinguish genetically-versus exposure-driven effects. We further leveraged our EWAS results to develop the first multi-CpG biomarker predictive of lifetime cannabis (ever vs. never) use.
METHODS AND MATERIALS

Study population
The Sister Study is a prospective cohort of 50,884 women ascertained across the US between 2003-2009 that was designed to examine environmental and genetic risk factors of breast cancer (10) . Women, aged 35-75 years old, were enrolled if they had a sister diagnosed with breast cancer and no personal history of breast cancer at baseline. Whole blood samples were collected, along with data from questionnaires and interviews covering demographics, lifestyle, family and medical history, and environmental exposures.
Since the study's inception, a number of sub-studies have been designed to address specific hypotheses related to women's health. For the current study, we used existing DNAm array data from a case-cohort study of 2,878 non-Hispanic white women designed to identify blood-based DNAm changes associated with incident breast cancer, as described previously (11, 12) . Briefly, the case-cohort study included a random sample of 1,336 women from the cohort and 1,542 additional women who later 
Cannabis assessment
Lifetime cannabis use was determined by response to the question, "Have you ever smoked marijuana?", asked along with questions about tobacco smoking during the baseline computer-assisted telephone interview. Basing our primary analysis on ever-use facilitated our evaluation of genetic data using the largest genome-wide association study (GWAS) of cannabis use reported to date (N = 184,765) which focused on ever-use only (13) . Age of initiation, duration of use, and frequency of use were also assessed in the Sister Study and were considered for secondary analyses in the current study. Sister Study questionnaires can be accessed at https://www.sisterstudystars.org/.
DNAm data, quality control (QC), and pre-processing
Blood sample collection and DNA extraction have been described previously (11, 12) . A total of 2,878 blood samples were assayed using the Illumina HumanMethylation450 array which covers >450,000 CpG sites targeting promoters, CpG islands, 5' and 3' untranslated regions, the major histocompatibility complex, and some enhancer regions (14) .
Data quality assessment and pre-processing was conducted using the R package, ENmix (15) . A series of diagnostic plots were generated to detect problematic samples, arrays, and laboratory plates. The ENmix pipeline was implemented for data pre-processing and included the following steps: background correction using the ENmix method (15) ; correction of fluorescent dye-bias using the RELIC method (16); inter-array quantile normalization; and correction of probe type bias using the RCP (regression on correlated CpGs) method (17) . Surrogate variables (SVs) of the array control probes were generated to adjust for technical artifacts. To control for cellular heterogeneity, blood cell type proportions (CD8T cells, CD4T cells, natural killer cells [NK], B cell, monocytes [Mono], and granulocytes [Gran]) were estimated following the Houseman method (18) . β-values, corresponding to the ratio of methylated intensities relative to the total intensity, were calculated to represent DNAm levels at each CpG.
Both sample-and probe-level exclusions were applied. In total, 295 samples were excluded due to poor bisulfite conversion efficiency (average bisulfite intensity <4000), outlier based on QC diagnostic plots (e.g., DNAm β-value distribution), low call rate (> 5% low quality data [Illumina detection P>1×10 -6 , number of beads <3, or values outside 3*Interquartile range (IQR)]), related individuals (one sister from each pair was selected at random for exclusion), missing phenotype data, or date of breast cancer diagnosis preceding blood draw. A total of 67,564 probes were excluded: 16,100 probes with > 5% low quality data; 14,522 probes with a common SNP (minor allele frequency >0.01) at the single base extension site or CpG site; 26,799 cross-reactive probes mapping to multiple genomic locations (19); 10,143 probes mapping to sex chromosomes. In addition, extreme DNAm β-value outliers were removed (outside 3*IQR); missing values were imputed using K-nearest neighbor. Following exclusions, the final analysis dataset included 2,583 women and 417,948 CpGs.
EWAS analysis
The Sister Study breast cancer case-cohort sample was randomly divided into discovery (2/3 of the overall sample: N=1,730 [855 ever users]) and replication (1/3 of the overall sample: N=853 [392 ever users]). Characteristics of the case-cohort sample used for analysis are provided in Tables 1 and S1.
For the EWAS, robust linear regression models were implemented using the R package, MASS (20) , to test the association between lifetime cannabis use (ever [used at least once in lifetime] versus never use) and methylation (β-value) at each CpG site, adjusting for age (continuous), incident breast cancer status (event, non-event), tobacco smoking (never, former, current), alcohol use (noncurrent, current), laboratory plate, DNA extraction method, six control SVs, and six blood cell type proportions. To adjust for multiple testing, the false discovery rate (FDR) was controlled at 10% (Benjamini and Hochberg) (21) . Replication analyses were conducted using the same set of covariates.
For replication, a Bonferroni correction was applied accounting for the number of CpGs tested.
A series of sensitivity analyses were conducted to assess other possible confounders. We considered the following: current perceived stress (derived from items 2, 6, 7, and 14 from the 14-item Perceived Stress Scale instrument (22) ; scale 0-20), family income while growing up (low income, middle income and well-off), body mass index (BMI) as calculated from height and weight measured by examiners at baseline (continuous), and self-reported history of depression (yes, no). To further rule out possible effects due to an association with subsequent breast cancer and use of alcohol and/or tobacco, we conducted stratified analyses by these variables. EPISTRUCTURE was implemented using the python toolset, GLINT (23), to rule out genetic confounding for significant EWAS findings. More specifically, the first four EPISTRUCTURE components (principal components) were computed, while accounting for estimated cell type proportions, and included as covariates in the model to adjust for population stratification.
Biomarker development and validation
We developed a multi-CpG classifier of lifetime cannabis use within the EWAS 
Follow-up analyses of replicable EWAS findings
To further characterize replicable EWAS findings, we examined the relationship between DNAm levels and total duration of use, divided into quartiles given the skewed missing information]). We also evaluated the effect of age of initiation (log transformed) on DNAm levels (N = 1,245 [N = 2 with missing information]; mean +/-SD: 20.85 ± 6.76 years). These secondary evaluations were restricted to these two exposure characteristics given the high degree of missing information (23%) and limited variability for frequency of use among ever users.
Our EWAS findings could be due to underlying genetic effects or the effect of exposure to cannabis. First, to explore whether genetic risk factors for lifetime cannabis use could explain our findings, we used the set of eight genome-wide significant single nucleotide polymorphisms (SNPs) identified in the most recent lifetime cannabis use GWAS meta-analysis (N = 184,765; European ancestry) (13) and the BIOS QTL browser (27) to identify CpGs associated with the cannabis use-associated SNPs in blood samples (i.e., determine if lifetime cannabis use-associated SNPs are cismethylation quantitative trait loci [cis-meQTLs] in blood). We then examined whether any of the CpGs we identified in our EWAS overlapped with these cis-meQTL-CpGs. Of note, cis-meQTLs provided through the BIOS QTL browser were identified using data on 3,841 Dutch individuals and modeled without accounting for any phenotype or exposure.
Next, we used the BIOS QTL browser (27) to identify blood-based cis-meQTLs for the lifetime cannabis-use associated CpGs observed in our EWAS. The Sister Study participants have been genotyped using the OncoArray that is customized to optimally capture cancer-associated SNPs (28) , but the 230,000 tagging SNP backbone does not provide sufficient coverage to directly model cis-meQTL associations with lifetime cannabis use in the Sister Study case-cohort sample. As such, we again used results from the lifetime cannabis use GWAS meta-analysis (N=162,082 with 23andMe samples removed) (13) and performed a look-up of the association between BIOSimplicated cis-meQTLs and lifetime cannabis use.
RESULTS
EWAS sample characteristics
On average, women who reported lifetime cannabis (ever) use were younger and more likely to report alcohol and tobacco use ( Table 1) . The prevalence of current tobacco smoking was low (7% of the total sample) and, among ever cannabis users, only half identified as a former tobacco smoker. Alcohol use was more prevalent in the sample with 10% of ever cannabis users reporting noncurrent use and only 3 individuals indicating never use. In addition, ever cannabis users were more likely to grow up in a family with higher income levels, have a lower BMI, and have a higher estimated proportion of CD8 T cells and a lower proportion of NK cells (Table S1 ). However, after controlling for age, the estimated cell type proportions were not associated (P>0.05) with lifetime cannabis use. There was also suggestive evidence in the discovery sample, but not in the replication sample, for differences between ever and never users by self-reported history of depression and current perceived stress (Table S1 ).
EWAS of lifetime cannabis use: Discovery and Replication
We identified one epigenome-wide significant association (FDR<0.10) at cg15973234 ( Figure 1 and Table S2 [EWAS results with unadjusted P<0.05]). Overall, effects sizes were small ( Figure S1) , and there was no evidence of inflation (λ=1.02; Figure S2 ). Further adjustment for potential confounders, including current perceived stress, family income while growing up, BMI, and history of depression did not substantively affect the overall results, thus the more parsimonious model remained our primary model (see Figures S3-S4 for model comparisons) .
The cg15973234-lifetime cannabis use association met a Bonferroni correction in the replication sample (PReplication=0.04, βReplication=-0.005; Table 2 ) and in the combined sample (PCombined=3.3×10 -8 , βCombined=-0.008; Table 2 ). In further testing of cg15973234 in the combined sample, we found that it was not associated with total duration of use (P=0.85; β=0.0005) or age of initiation (P=0.35; β=0.01).
Additional sensitivity analyses designed to further evaluate possible effects of cigarette smoking, alcohol use, incident breast cancer, and genetic ancestry on our observed cg15973234 association did not suggest significant confounding (Table S3 ).
The lifetime cannabis use-associated cg15973234 lies within a CpG island spanning the 5' untranslated region of the cell migration inducing hyaluronidase 1 (CEMIP) gene. The adjacent CpGs in the island are located within 1kb of cg15973234 but are not highly correlated with cg15973234 and thus provide minimal support for the EWAS signal (Table S4 ). The most highly correlated CpG within the region (cg24159335; Pearson correlation [r] with cg15973234=0.29) has a similar mean DNAm β-value and is nominally associated with lifetime cannabis use with a direction of effect consistent with cg15973234 (P=3.2×10 -3 ; β=-0.003; Table S4 ).
Blood-based DNAm biomarker of lifetime cannabis use
Using the top 5 most significant CpGs (EWAS discovery P<1×10 -5 ) as input into LASSO regression for model training resulted in a classifier composed of three CpGs: cg15973234 (CEMIP), cg04685163 (DLGAP2), and cg03765885 (intergenic) ( Table   S5) (Table S6) 
Follow-up of replicable EWAS finding
None of the eight reported lifetime cannabis use-associated SNPs, from the largest GWAS to date (N=184,765) (13) , are cis-meQTLs of cg15973234 as they are not located on the same chromosome as our EWAS finding. To further assess the possibility that there may be other, weaker genetic risk factors of cannabis use driving our EWAS finding, we used the BIOS QTL browser and identified two independent cis-meQTLs for cg15973234 in blood (rs3848177 and rs8025670; FDR<0.05), as determined by statistical modeling of cis-meQTL effects (27) . To assess the genetic association between these common SNPs and lifetime cannabis use, we again used results from the lifetime cannabis use GWAS meta-analysis (13) and found no association ( Table 3) .
DISCUSSION
We report the first blood-based EWAS of cannabis use where we identified and replicated a difference between ever and never users in DNAm levels at cg15973234 (CEMIP). DNAm at this site is not correlated with reported cannabis-associated SNPs (13) , suggesting that our finding is unlikely to be genetically-driven and more likely related to the cannabis exposure. Further characterization of the cg15973234-lifetime cannabis use association indicated that the finding appears robust to total duration of use and age of initiation, suggesting that this CpG within CEMIP acts as a general indicator of lifetime cannabis use (i.e., a marker of ever versus never use).
CEMIP plays a role in hyaluronan binding and degradation (30) and has been implicated in nonsyndromic hearing loss (31) , autoimmune disorders (30, 32) , and various cancers (33) (34) (35) . Hyaluronan, one of the main components of the extracellular matrix, is an important regulator of inflammation (36) and immune processes (37) .
Although cannabinoids are thought to play a role in immunoregulation and have antiinflammatory properties (38) , there is little evidence to date that those processes are modulated by CEMIP or downstream genes in the CEMIP pathway (39, 40) .
Our work identifies the first multi-CpG DNAm biomarker of cannabis use, demonstrating in an independent replication sample that lifetime cannabis use can be correctly categorized using DNAm at three CpGs, including our top signal at cg15973234 within CEMIP (AUC=0.79). The cannabis-associated CpG with the largest (magnitude) LASSO coefficient in the model (cg04685163) is located 10 base pairs away from a DLGAP2 (DLG associated protein 2) transcription start site. Notably, DLGAP2 is a post-synaptic density protein which has been associated with various neuropsychiatric disorders (e.g., schizophrenia) (41) . A recent study investigating DNAm changes in sperm related to human cannabis use reported at least ten differentially methylated CpGs in DLGAP2 (9) . Further, DLGAP2 exhibits both increased and decreased intronic DNAm, as well as increased mRNA expression in association with parental THC exposure in the rat nucleus accumbens (42) .
While prior evidence suggests cannabis-related epigenetic changes in brain for DLGAP2, in the case of epigenetic biomarkers for substance use there is no a priori expectation that genes dysregulated in blood will reflect neurobiological mechanisms underlying substance use. DNAm profiles differ across tissues and cell types and studies conducted using a more biologically relevant brain tissue (e.g., nucleus accumbens, prefrontal cortex) would be needed to inform the neurobiology of cannabis use disorder (43) . Once brain-based DNAm marks in humans (necessitating postmortem tissues) have been identified, however, these results could be used to identify blood proxies of exposure for overlapping blood-and brain-based DNAm changes related to lifetime cannabis use.
Our findings support DNAm as a promising candidate marker for cannabis use.
However, our study has limitations. Our findings may not be fully generalizable due to the case-cohort design (i.e., restricted to non-Hispanic Caucasian women and further enriched for women who subsequently developed breast cancer). Although our study relied on self-reported lifetime cannabis use, which could lead to underreporting and misclassification, these factors would tend to bias towards the null resulting in loss of statistical power. In addition to self-reported lifetime cannabis use, frequency of use was collected; however, the low level of response to this question limited its use to evaluate dose-response. Further, inaccurate and incomplete recall could affect those data, as the average time since first use was 32.6 ± 6.1 years ago with an average total duration of use of 4.6 ± 7.2 years. Time since last use was not collected to assess recency of use.
Finally, we cannot rule out the effect of other illicit drugs (e.g., cocaine, opioids) as those data were not collected in the Sister Study. However, we expect the prevalence of other illicit drug use to be low in this cohort. We also do not suspect that our findings are driven by breast cancer, or the use of tobacco and alcohol. In the largest EWAS of tobacco smoking to date (6), cg15973234 was not identified as one of the 18,760 CpGs associated with current and/or former smoking (FDR<0.05), or in the largest EWAS of alcohol to date (44) , as one of the 363 CpGs associated with alcohol consumption (P<1×10 -7 ). Further, cg15973234 was not reported as one of the 2,098 replicated breast cancer-associated CpGs in the most recent breast cancer EWAS (45) .
Our results provide evidence that blood-based DNAm can inform cannabis use histories and support a surprisingly effective classifier able to categorize ever versus never cannabis users based on DNAm levels at three CpG sites: AUC=0.79 (95% confidence interval [0.76, 0.82]). We anticipate that larger sample sizes and richer phenotype data will enable us to develop more precise DNAm biomarkers, including those indicative of cannabis-related health outcomes. Combined 2,583 -0.008 0.001 3.32×10 -8 a Probe located within the gene, CEMIP (chr15:81072152; GRCh37/hg19 build) b FDR adjusted P-value=0.06 Abbreviation: SE: standard error 
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